Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02004652
Other study ID # RIGS-2013-PRU
Secondary ID
Status Completed
Phase Phase 2
First received November 26, 2013
Last updated September 29, 2016
Start date November 2013
Est. completion date December 2014

Study information

Verified date September 2016
Source Jinling Hospital, China
Contact n/a
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effect and safety of prucalopride on recovery of gastrointestinal function in patient undergoing major gastrointestinal surgery. The investigators hypothesize that patients who take prucalopride after major gastrointestinal surgery will have shorter duration of postoperative ileus.


Description:

Postoperative ileus (POI), an interruption of bowel motility function, virtually occurs in all patients undergoing major gastrointestinal(GI) surgery. This functional impairment persists for a variable duration, usually resolving within 1 day in the small intestine, 1 to 3 days in the stomach and 3 to 5 days in the colon. Therefore, time of return of colonic function is the the major determinant of duration of POI. Attempts to reduce the duration of POI have prompted the implementation of fast track surgery including early removal of the nasogastric tube, early feeding, alvimopan, gum chewing, and prompt ambulation. However, it is still reported to be more than 4-5 days in most of the randomized trial. Therefore, methods specifically aiming at promoting postoperative colon motility may further enhance the GI function recovery, and prucalopride may be one of the options.

Prucalopride, a substituted benzamide with selective 5-HT4 agonist activity, has been shown previously to significant improve colon motility and transit, but it only has mild effect on gastric or small bowel transit. The drug is well tolerated with no significant adverse effects. Recently, prucalopride has been approved in Europe and America for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. However, its usage in the postoperative period has not been tested. This study will test the ability and safety of prucalopride given 24hrs after GI surgery to hasten the recovery of GI function.


Recruitment information / eligibility

Status Completed
Enrollment 110
Est. completion date December 2014
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Consecutive patients undergoing elective gastric, small bowel, or partial colonic resection via laparotomy or laparoscopy.

2. Patients with American Society of Anaesthesiologists grading I-III

3. Informed consent available.

Exclusion Criteria:

1. Patients with stoma creation, extensive adhesiolysis, total or subtotal colectomy , or patients who had a history of total or subtotal colectomy.

2. Patients who developed intraoperative problems or complications, or had peritoneal carcinomatosis.

3. Patients who developed serious complications within 24 hours after surgery.

4. Those who received epidural anesthesia or analgesia.

5. Patients who received other prokinetic drugs.

6. Patients who were allergic to prucalopride.

7. Patients with severe comorbidity and/or organ(kidney, liver, and heart) dysfunction

8. Patients had complete bowel obstruction

9. Patients who have participated other clinical trials.

10. Patients who have short bowel(<200cm small bowel) or history of constipation.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Prucalopride
Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment
Placebo
Vitamin, 50mg, tablet.

Locations

Country Name City State
China Department of Generay Surgery, Jinling hosptal, Medical School of Nanjing University Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Jinling Hospital, China

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Whole blood white blood cell(WBC) count on postoperative day 1 and 3 whole blood white blood cell (WBC) count(*109/L) postoperative day 1 and 3 No
Other Whole blood neutrophil percentage on postoperative day 1 and 3 neutrophil percentage(%) postoperative day 1 and 3 No
Other Whole blood platelet level on postoperative day 1 and 3 platelet level(*109/L) postoperative day 1 and 3 No
Other Serum C-reactive protein(CRP) level on postoperative day 1 and 3. CRP level(mg/dL) postoperative day 1 and 3 No
Other Serum interleukin-6(IL-6) level on postoperative day 1 and 3. IL-6(pg/ml) postoperative day 1 and 3 No
Other Serum procalcitonin(PCT) level on postoperative day 1 and 3. PCT(ug/L) postoperative day 1 and 3 No
Primary Time to defaecation, measured in hours, from the time the surgery ends till the first observed passage of stool up to 30 days after surgery No
Secondary Time of first passing flatus reported by the patients(hours) up to 30 days after surgery No
Secondary Time to resume solid diet or total enteral nutrition(TEN)(days) up to 30 days after surgery No
Secondary Length of postoperative hospital stay (LOS)(days) participants will be followed for the duration of postoperative hospital stay, an expected average of 8 days No
Secondary Overall post-operative complication rate defined according to the Clavien-Dindo Classification up to 30 days after surgery No
Secondary Overall cost (RMB) participants will be followed for the duration of postoperative hospital stay, an expected average of 8 days No
Secondary Pain scores on visual analogue scale (from 0 which implies no pain at all, to 10 which implies the worst pain imaginable) on the first 3 postoperative days and postoperative analgesic requirement (number of doses on 50-mg Pethidine) up to postoperative day 3 No
Secondary Time to walk independently(days) up to 30 days after surgery No
Secondary Hospital Readmission Rates Post 30-day Discharge up to 30 days after discharge No
Secondary Length of postoperative ICU stay (days) up to 30 days after surgery No
Secondary Incidence of adverse events related to drug usage Diarrhoea,Flatulence,Nausea,Abdominal pain,Headaches,Menstrual disorder,Dizziness ,Skeletal pain,ECG nodal arrhythmia up to 7 days after drug usage Yes
Secondary Reinsertion of nasogastric tube up to 30 days after surgery No
See also
  Status Clinical Trial Phase
Recruiting NCT04205058 - Coffee After Pancreatic Surgery N/A
Completed NCT02232893 - Effect of TU-100 in Patients Undergoing Laparoscopic Colectomy Phase 2
Not yet recruiting NCT05001763 - Prucalopride for Postoperative Ileus in Patients Undergoing Robot-assisted Laparoscopic Radical Cystectomy Phase 2
Active, not recruiting NCT04547868 - Can Coffee/Caffeine Improve Post-Operative Gastrointestinal Recovery N/A
Completed NCT02815956 - Tibial Nerve Stimulation and Postoperative Ileus N/A
Completed NCT02947269 - Prucalopride in Postoperative Ileus Phase 3
Recruiting NCT05512741 - Intestinal Microbiota and Postoperative Ileus After Colorectal Surgery
Recruiting NCT04675606 - Implementing a Low Fiber Diet vs. Regular Diet in Postoperative Colorectal Patients With Ileostomies N/A
Completed NCT02161367 - Effect of Simethicone on Postoperative Ileus in Patients Undergoing Colorectal Surgery Phase 4
Completed NCT01956643 - Effect of Sham Feeding on Postoperative Ileus After Elective Liver Transplantation N/A
Completed NCT00464425 - Electroacupuncture for Postoperative Ileus After Laparoscopic Colorectal Surgery Phase 3
Completed NCT00402961 - Trial of Acupuncture for Reduction of Post-Colectomy Ileus Phase 2
Terminated NCT04100265 - ANTERO-5: Gastric Motility in Postoperative Ileus N/A
Recruiting NCT04090073 - Electroacupuncture Combined With Fast-track Perioperative Program for Laparoscopic Colorectal Surgery N/A
Recruiting NCT03222557 - Electroacupuncture for Postoperative Ileus After Laparoscopic Surgery for Mid and Low Rectal Cancer N/A
Withdrawn NCT02261454 - RCT Gum Chewing on Bowel Function After Abdominal Surgery in Children N/A
Completed NCT02639728 - The Effect of Coffee Consumption in Enhancing Recovery of Bowel Function Following Colorectal Surgery. N/A
Completed NCT00509327 - Randomized Clinical Trial of Bisacodyl Versus Placebo on Postoperative Bowel Motility in Elective Colorectal Surgery Phase 4
Completed NCT03097900 - Does Caffeine Enhance Bowel Recovery After Colorectal Surgery? Phase 2
Completed NCT03143621 - The Effect of Coffee After Resection of Small Bowel N/A